Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”

Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic” Publisher Pubmed

Shakshouk H^{1, 2} ; Daneshpazhooh M³ ; Murrell DF⁴ ; Lehman JS¹

Show Affiliations

1. Department of Dermatology, Mayo Clinic, Rochester, MN, United States
2. Department of Dermatology, Andrology and Venereology, Alexandria University, Egypt
3. Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Iran
4. Department of Dermatology, University of New South Wales, Sydney, Australia

Source: Journal of the American Academy of Dermatology Published:2021

Abstract

[No abstract available]

2. Covid Vaccination in Patients Under Treatment With Rituximab: A Presentation of Two Cases From Iran and a Review of the Current Knowledge With a Specific Focus on Pemphigus, Dermatologic Therapy (2022)

3. Adverse Outcome and Severity of Covid-19 in Patients With Autoimmune Bullous Diseases: A Historical Cohort Study, Dermatologic Therapy (2022)

4. Covid-19: The Experience From Iran, Clinics in Dermatology (2021)

5. Treatment Concerns for Bullous Pemphigoid in the Covid-19 Pandemic Era, Dermatologic Therapy (2020)

6. The Efficacy of Rituximab in Patients With Mucous Membrane Pemphigoid, Journal of Dermatological Treatment (2022)

Experts (# of related papers)

View all Related Experts

Maryam Daneshpajooh (5)

Hamid Reza Mahmoodi (4)

Style	Citing Format
MLA	Shakshouk H, et al.. "Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”." Journal of the American Academy of Dermatology, vol. 84, no. 1, 2021, pp. e61-e62.
APA	Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS (2021). Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”. Journal of the American Academy of Dermatology, 84(1), e61-e62.
Chicago	Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS. "Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”." Journal of the American Academy of Dermatology 84, no. 1 (2021): e61-e62.
Harvard	Shakshouk H et al. (2021) 'Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”', Journal of the American Academy of Dermatology, 84(1), pp. e61-e62.
Vancouver	Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS. Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”. Journal of the American Academy of Dermatology. 2021;84(1):e61-e62.
BibTex	@article{ author = {Shakshouk H and Daneshpazhooh M and Murrell DF and Lehman JS}, title = {Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”}, journal = {Journal of the American Academy of Dermatology}, volume = {84}, number = {1}, pages = {e61-e62}, year = {2021} }
RIS	TY - JOUR AU - Shakshouk H AU - Daneshpazhooh M AU - Murrell DF AU - Lehman JS TI - Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic” JO - Journal of the American Academy of Dermatology VL - 84 IS - 1 SP - e61 EP - e62 PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract